Literature DB >> 16146720

Phytate (Myo-inositol hexakisphosphate) inhibits cardiovascular calcifications in rats.

Felix Grases1, Pilar Sanchis, Joan Perello, Bernat Isern, Rafel Maria Prieto, Carlos Fernandez-Palomeque, Miguel Fiol, Oriol Bonnin, Jose Juan Torres.   

Abstract

Calcification is an undesirable disorder, which frequently occurs in the heart vessels. In general, the formation of calcific vascular lesions involves complex physicochemical and molecular events. Calcification (hydroxyapatite) is initiated by injury and is progressed by promoter factors and/or the deficit of inhibitory signals. Myo-inositol hexakisphosphate (phytate, InsP6) is found in organs, tissues and fluids of all mammals and exhibits an important capacity as a crystallization inhibitor of calcium salts in urine and soft tissues. The levels found clearly depend on the dietary intake but it can also be absorbed topically. In this paper, the capacity of InsP6 as a potential inhibitor of cardiovascular calcifications was assessed in Wistar rats. Three groups were included, a control group, an InsP6 treated group (subjected to calcinosis induction by Vitamin D and nicotine and treated with standard cream with a 2% of InsP6 as potassium salt) and an InsP6 non-treated group (only subjected to calcinosis induction). All rats were fed AIN 76-A diet (a purified diet in which InsP6 is undetectable). Animals were monitorized every 12 hours. After 60 hours of calcinosis treatment, all rats of the InsP6 non-treated group died and the rest were sacrificed. Aortas and hearts were removed. A highly significant increase in the calcium content of aorta and heart tissue was observed in the InsP6 non-treated rats (21 +/- 1 mg calcium/g dry aorta tissue, 10 +/- 1 mg calcium/g dry heart tissue) when compared with controls (1.3 +/- 0.1 mg calcium/g dry aorta tissue, 0.023 +/- 0.004 mg calcium/g heart dry tissue) and InsP6 treated (0.9 +/- 0.2 mg calcium/g dry aorta tissue, 0.30 +/- 0.03 mg calcium/g dry heart tissue) animals. Only InsP6 non-treated rats displayed important mineral deposits in aorta and heart. These findings are consistent with the action of InsP6, as an inhibitor of calcification of cardiovascular system.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16146720     DOI: 10.2741/1786

Source DB:  PubMed          Journal:  Front Biosci        ISSN: 1093-4715


  21 in total

1.  Protective effect of myo-inositol hexaphosphate (phytate) on bone mass loss in postmenopausal women.

Authors:  Angel A López-González; Félix Grases; Nieves Monroy; Bartolome Marí; Ma Teófila Vicente-Herrero; Fernando Tur; Joan Perelló
Journal:  Eur J Nutr       Date:  2012-05-22       Impact factor: 5.614

2.  A phase 1b randomized, placebo-controlled clinical trial with SNF472 in haemodialysis patients.

Authors:  Carolina Salcedo; Pieter H Joubert; Miguel D Ferrer; Ana Z Canals; Francisco Maduell; Vicens Torregrosa; Josep Maria Campistol; Raquel Ojeda; Joan Perelló
Journal:  Br J Clin Pharmacol       Date:  2019-02-19       Impact factor: 4.335

Review 3.  An update on vascular calcification and potential therapeutics.

Authors:  Anubha Singh; Simran Tandon; Chanderdeep Tandon
Journal:  Mol Biol Rep       Date:  2021-01-04       Impact factor: 2.316

Review 4.  Detection, removal and prevention of calculus: Literature Review.

Authors:  Deepa G Kamath; Sangeeta Umesh Nayak
Journal:  Saudi Dent J       Date:  2013-12-18

5.  First-time-in-human randomized clinical trial in healthy volunteers and haemodialysis patients with SNF472, a novel inhibitor of vascular calcification.

Authors:  J Perelló; P H Joubert; M D Ferrer; A Z Canals; S Sinha; C Salcedo
Journal:  Br J Clin Pharmacol       Date:  2018-10-03       Impact factor: 4.335

6.  Effects of Mediterranean diets with low and high proportions of phytate-rich foods on the urinary phytate excretion.

Authors:  Rafael M Prieto; M Fiol; J Perello; R Estruch; E Ros; P Sanchis; F Grases
Journal:  Eur J Nutr       Date:  2010-01-28       Impact factor: 5.614

7.  Effects of Myo-inositol Hexaphosphate (SNF472) on Bone Mineral Density in Patients Receiving Hemodialysis: An Analysis of the Randomized, Placebo-Controlled CaLIPSO Study.

Authors:  David A Bushinsky; Paolo Raggi; Jordi Bover; Markus Ketteler; Antonio Bellasi; Mariano Rodriguez; Smeeta Sinha; Rekha Garg; Joan Perelló; Alex Gold; Glenn M Chertow
Journal:  Clin J Am Soc Nephrol       Date:  2021-04-07       Impact factor: 8.237

Review 8.  ABCC6, Pyrophosphate and Ectopic Calcification: Therapeutic Solutions.

Authors:  Briana K Shimada; Viola Pomozi; Janna Zoll; Sheree Kuo; Ludovic Martin; Olivier Le Saux
Journal:  Int J Mol Sci       Date:  2021-04-27       Impact factor: 5.923

9.  Renal papillary calcification and the development of calcium oxalate monohydrate papillary renal calculi: a case series study.

Authors:  Fèlix Grases; Antonia Costa-Bauzá; Rafel M Prieto; Antonio Conte; Antonio Servera
Journal:  BMC Urol       Date:  2013-03-11       Impact factor: 2.264

10.  Inositol hexakisphosphate inhibits osteoclastogenesis on RAW 264.7 cells and human primary osteoclasts.

Authors:  María del Mar Arriero; Joana M Ramis; Joan Perelló; Marta Monjo
Journal:  PLoS One       Date:  2012-08-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.